CannMart Marks International Debut with First Shipment of Cannabis Products to Australia - Seite 3

The forward-looking information contained herein, including, without limitation, statements related to the expected impact of CannMart’s products in the Australian medical cannabis market and general expectations relating to the Company’s international expansion strategy, are based on assumptions management believed to be reasonable at the time such statements were made, including without limitation, that the Australian medical cannabis industry will develop as anticipated, expectations relating to anticipated sales of CannMart’s products, including Roilty in particular, expectations that Roilty will gain market acceptance, as well as other considerations that are believed to be appropriate in the circumstances are made as of the date of this news release and is based on assumptions management believed to be reasonable at the time such statements were made. While we consider these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct. 

By its nature, forward-looking information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. Such factors include, without limitation: the growth and demand for quality cannabis products in Australia not being as anticipated, the failure of CannMart’s premium cannabis products to gain market acceptance as anticipated, the Australian medical cannabis market’s failure to continue to develop and grow, in a timely manner, if at all, the Company’s failure to develop its Cannabis business in Australia as anticipated and to realize on the anticipated benefits therefrom, unanticipated changes to current regulations that would adversely impact its business in Australia, and risks relating to the Company’s ability to execute its business strategy and the benefits realizable therefrom. Additional risk factors can also be found in the Company’s current MD&A filed under the Company’s SEDAR+ profile at www.sedarplus.ca. Readers are cautioned not to put undue reliance on forward-looking information. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.